Movano INC 8-K filings

Movano Health announced its Q2 2024 financial results, highlighted by preparations for the Evie Ring relaunch and advancements in the EvieMED medical device.

Movano Inc. stockholders approved an increase in authorized shares, an amendment to the 2019 Omnibus Incentive Plan, and a potential reverse stock split at the 2024 Annual Meeting.

Movano Inc. has amended its At-the-Market Issuance Agreement, replacing B. Riley Securities with JonesTrading Institutional Services as the sales agent.

Movano Health announced its Q1 2024 financial results, highlighted by a $24.1 million private placement and progress towards FDA clearance for its Evie Med Ring.

Movano Health announced a $24 million private placement, 2023 financial results, and progress towards FDA clearance for its Evie Med device.

Movano Inc. has entered into a securities purchase agreement for a private placement of units consisting of common stock or pre-funded warrants and common stock purchase warrants, aiming to raise up to $42.6 million.